Retrospective observational study of HER2 immunohistochemistry in borderline breast cancer patients undergoing neoadjuvant therapy, with an emphasis on Group 2 (HER2/CEP17 ratio ≥2.0, HER2 copy number

Quantitative digital imaging analysis of HER2 immunohistochemistry predicts the response to anti-HER2 neoadjuvant chemotherapy in HER2-positive breast carcinoma

(2020) Aidan C. Li et al.   BREAST CANCER RESEARCH AND TREATMENT

Impact of the Updated 2018 American Society of Clinical Oncology/College of American Pathologists Guideline for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer

(2020) Anqi Li et al.   ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

A clinicopathological study of 30 breast cancer cases with a HER2/CEP17 ratio of ≥2.0 but an average HER2 copy number of

(2020) Xiaoling Wang et al.   MODERN PATHOLOGY

Applying the New Guidelines of HER2 Testing in Breast Cancer

(2020) Huina Zhang et al.   Current Oncology Reports

A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer

(2019) J Veeraraghavan et al.   ANNALS OF ONCOLOGY

Pathologic complete response rate according to HER2 detection methods in HER2-positive breast cancer treated with neoadjuvant systemic therapy

(2019) Melissa Krystel-Whittemore et al.   BREAST CANCER RESEARCH AND TREATMENT

Clinicopathologic factors associated with response to neoadjuvant anti-HER2-directed chemotherapy in HER2-positive breast cancer

(2019) Jane L. Meisel et al.   Clinical Breast Cancer

Survival Analysis After Neoadjuvant Chemotherapy With Trastuzumab or Lapatinib in Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer in the GeparQuinto (G5) Study (GBG 44)

(2018) Michael Untch et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor–Positive Metastatic Breast Cancer: ALTERNATIVE

(2018) Stephen R.D. Johnston et al.   JOURNAL OF CLINICAL ONCOLOGY

Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update

(2018) Antonio C. Wolff et al.   JOURNAL OF CLINICAL ONCOLOGY

HER2Gene Amplification Testing by Fluorescent In Situ Hybridization (FISH): Comparison of the ASCO-College of American Pathologists Guidelines With FISH Scores Used for Enrollment in Breast Cancer International Research Group Clinical Trials

(2016) Michael F. Press et al.   JOURNAL OF CLINICAL ONCOLOGY

‘Non-classical’ HER2 FISH results in breast cancer: a multi-institutional study

(2016) Morgan Ballard et al.   MODERN PATHOLOGY

Effects of Estrogen Receptor and Human Epidermal Growth Factor Receptor-2 Levels on the Efficacy of Trastuzumab

(2016) Sherene Loi et al.   JAMA Oncology

Research-Based PAM50 Subtype Predictor Identifies Higher Responses and Improved Survival Outcomes in HER2-Positive Breast Cancer in the NOAH Study

(2014) A. Prat et al.   CLINICAL CANCER RESEARCH

Updated UK Recommendations for HER2 assessment in breast cancer

(2014) Emad A Rakha et al.   JOURNAL OF CLINICAL PATHOLOGY

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

(2014) Patricia Cortazar et al.   LANCET

Human epidermal growth factor receptor 2 (HER2)-positive and hormone receptor-positive breast cancer: new insights into molecular interactions and clinical implications

(2013) F. Montemurro et al.   ANNALS OF ONCOLOGY

Bevacizumab plus preoperative chemotherapy in operable HER2 negative breast cancer: biomarkers and pathologic response

(2013) P. Sánchez-Rovira et al.   Clinical & Translational Oncology

Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update

(2013) Antonio C. Wolff et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

(2011) Luca Gianni et al.   LANCET ONCOLOGY

Disease-Free Survival According to Degree ofHER2Amplification for Patients Treated With Adjuvant Chemotherapy With or Without 1 Year of Trastuzumab: The HERA Trial

(2009) Mitch Dowsett et al.   JOURNAL OF CLINICAL ONCOLOGY

Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth Factor Receptor 2–Positive, Hormone Receptor–Positive Metastatic Breast Cancer: Results From the Randomized Phase III TAnDEM Study

(2009) Bella Kaufman et al.   JOURNAL OF CLINICAL ONCOLOGY